Zynex (NASDAQ:ZYXI – Get Free Report) issued its quarterly earnings results on Thursday. The company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04), Briefing.com reports. The company had revenue of $49.88 million during the quarter, compared to analysts’ expectations of $51.99 million. Zynex had a return on equity of 16.34% and a net margin of 4.33%. The business’s quarterly revenue was up 11.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.09 EPS.
Zynex Price Performance
NASDAQ ZYXI traded down $1.26 during trading on Friday, hitting $8.93. 1,034,596 shares of the stock traded hands, compared to its average volume of 195,244. The company has a market capitalization of $283.75 million, a P/E ratio of 38.83 and a beta of 0.53. The firm has a 50-day simple moving average of $9.55 and a 200-day simple moving average of $11.06. The company has a quick ratio of 2.87, a current ratio of 3.58 and a debt-to-equity ratio of 1.76. Zynex has a 12-month low of $6.88 and a 12-month high of $13.77.
Analyst Upgrades and Downgrades
ZYXI has been the subject of a number of recent analyst reports. Royal Bank of Canada dropped their price objective on Zynex from $15.00 to $12.00 and set an “outperform” rating for the company in a research note on Friday. HC Wainwright dropped their price objective on Zynex from $21.00 to $16.00 and set a “buy” rating for the company in a research note on Friday.
Zynex Company Profile
Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.
Read More
- Five stocks we like better than Zynex
- What is a Low P/E Ratio and What Does it Tell Investors?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- How to Most Effectively Use the MarketBeat Earnings Screener
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- How to invest in marijuana stocks in 7 steps
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.